Concepedia

Esther Redín

ER

Statistics

Publications

15

Citations

504

H-Index

12

Active since

2017

Affiliations

Universidad de Navarra(Current)

Centro de Investigación Biomédica en Red de Cáncer

Instituto de Salud Carlos III

Clinica Universidad de Navarra

Memorial Sloan Kettering Cancer Center

Esther Redín is an author at Universidad de Navarra specializing in molecular oncology, oncology, and medicine.

ORCID

Publications per year

2017–2025

15

Publications

15

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Esther Redín, Irati Garmendia, Teresa Lozano et al. · Journal for ImmunoTherapy of Cancer · 2021 · 93 citations · Full text

, , +17

PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Francisco Expósito, Miriam Redrado, Maeva Houry et al. · Cancer Research · 2023 · 78 citations

, , +17

miR-146a targets c-met and abolishes colorectal cancer liver metastasis

Anne‐Marie Bleau, Miriam Redrado, Estanislao Nistal‐Villán et al. · Cancer Letters · 2017 · 51 citations

, , +14

Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

Tongchen He, Lanbo Xiao, Yuanyuan Qiao et al. · Cancer Cell · 2024 · 47 citations · Full text

, , +12

Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers

Àlvaro Quintanal-Villalonga, Vidushi Durani, Amin H. Sabet et al. · Science Translational Medicine · 2023 · 44 citations · Full text

, , +15

1–5 of 15